Evelyn Partners Investment Management LLP Sells 1,863 Shares of Stryker Corporation $SYK

Evelyn Partners Investment Management LLP trimmed its position in shares of Stryker Corporation (NYSE:SYK) by 0.7% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 265,451 shares of the medical technology company’s stock after selling 1,863 shares during the period. Stryker makes up approximately 2.4% of Evelyn Partners Investment Management LLP’s holdings, making the stock its 11th biggest holding. Evelyn Partners Investment Management LLP’s holdings in Stryker were worth $87,225,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Godfrey Financial Associates Inc. bought a new stake in Stryker in the fourth quarter worth $26,000. Sankala Group LLC bought a new position in Stryker during the fourth quarter valued at $26,000. United Financial Planning Group LLC purchased a new position in shares of Stryker in the 3rd quarter worth $27,000. Atlas Capital Advisors Inc. bought a new stake in shares of Stryker in the 4th quarter worth about $27,000. Finally, DJE Kapital AG bought a new stake in shares of Stryker in the 4th quarter worth about $28,000. 77.09% of the stock is owned by hedge funds and other institutional investors.

Stryker Price Performance

Stryker stock opened at $337.31 on Tuesday. Stryker Corporation has a 12-month low of $281.00 and a 12-month high of $404.14. The company has a current ratio of 2.11, a quick ratio of 1.25 and a debt-to-equity ratio of 0.62. The firm has a 50-day moving average price of $315.18 and a 200-day moving average price of $335.37. The firm has a market capitalization of $129.31 billion, a PE ratio of 39.04, a price-to-earnings-growth ratio of 2.12 and a beta of 0.77.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing the consensus estimate of $2.98 by ($0.38). Stryker had a net margin of 13.20% and a return on equity of 23.42%. The firm had revenue of $6.02 billion for the quarter, compared to the consensus estimate of $6.34 billion. During the same quarter in the previous year, the company posted $2.84 earnings per share. The business’s revenue for the quarter was up 2.6% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, equities research analysts forecast that Stryker Corporation will post 14.99 EPS for the current year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be given a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 1.0%. The ex-dividend date of this dividend is Tuesday, June 30th. Stryker’s payout ratio is 40.74%.

Analyst Ratings Changes

A number of research analysts recently commented on SYK shares. Evercore set a $350.00 price target on shares of Stryker in a report on Monday, July 6th. The Goldman Sachs Group reissued a “neutral” rating and set a $361.00 price objective on shares of Stryker in a research note on Friday, May 1st. Truist Financial restated a “hold” rating and set a $330.00 price objective (down from $380.00) on shares of Stryker in a research report on Monday, May 4th. Sanford C. Bernstein set a $410.00 price objective on Stryker in a research note on Friday, May 1st. Finally, Needham & Company LLC dropped their target price on Stryker from $454.00 to $418.00 and set a “buy” rating for the company in a report on Friday, May 1st. One investment analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $392.52.

Insiders Place Their Bets

In other news, VP M Kathryn Fink sold 5,220 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $283.85, for a total transaction of $1,481,697.00. Following the transaction, the vice president directly owned 13,137 shares of the company’s stock, valued at approximately $3,728,937.45. This trade represents a 28.44% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Robert S. Fletcher sold 4,544 shares of Stryker stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the sale, the vice president directly owned 10,582 shares of the company’s stock, valued at $3,247,298.34. This represents a 30.04% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 323,264 shares of company stock worth $100,659,489 in the last three months. Corporate insiders own 4.60% of the company’s stock.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.